新辅助化疗治疗晚期子宫内膜癌患者的疗效及对患者血清CA19-9、HE4、TGF-β1水平的影响

doi:10.3969/j.issn.1671-7171.2023.03.005

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1134 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要【目的】探讨新辅助化疗(NACT)治疗晚期子宫内膜癌(EC)患者的疗效及对患者血清糖类抗原199(CA19-9)、人附睾蛋白4(HE4)、转化生长因子-β1(TGF-β1)水平的影响。【方法】选择2015年1月至2019年12月在榆林市第二医院诊治的112例晚期EC患者,按照随机数字表法分为观察组和对照组,每组56例,两组均在腹腔镜下行子宫内膜癌根治术,观察组术前行NACT治疗,术后行常规化疗,对照组术后行常规化疗。比较两组手术相关指标、Ⅲ～Ⅳ级毒副反应发生率、3年生存率及治疗前后血清CA19-9、HE4、TGF-β1等肿瘤标志物水平。【结果】观察组患者术中出血量、手术时间、住院时间均少于对照组患者,差异具有统计学意义(P<0.05);治疗后,观察组血清CA19-9、HE4、TGF-β1水平均低于对照组(P<0.05);两组患者Ⅲ～Ⅳ级毒副反应发生率和3年生存率比较,差异无统计学意义(P>0.05)。【结论】NACT治疗晚期EC患者,可将不可手术病灶降期为可手术病灶,术后恢复快,还可抑制CA19-9、HE4、TGF-β1生成,且并不会显著增加毒副反应,值得临床推广应用。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	王榆平
	康红梅

关键词 ：子宫内膜肿瘤, 化学疗法,辅助, CA19-9抗原/血液, 附睾分泌蛋白质类/血液, 转化生长因子β1/血液

Abstract：【Objective】 To study the effects of neoadjuvant chemotherapy (NACT) on serum carbohydrate antigen 199 (CA19-9),human epididymal protein 4 (HE4) and transforming growth factor-β1 (TGF-β1) in the treatment of advanced endometrial carcinoma (EC). 【Methods】 A total of 112 patients with advanced EC treated in Second Hospital of Yulin from January 2015 to December 2019 were selected and divided into the observation group and the control group according to random number table method,with 56 patients in each group. The two groups underwent laparoscopic radical gastrectomy for endometrial cancer. The observation group received NACT before surgery and routine chemotherapy after surgery,while the control group only received routine chemotherapy after surgery. Operation related indicators,serum CA19-9,HE4,TGF-β1 and other tumor markers before and after treatment,the toxicity (Ⅲ-Ⅳ) and 3-year survival of the two groups were observed and compared. 【Results】 The intraoperative blood loss,operation time and hospitalization time of the observation group were all less than those of the control group,and the differences were statistically significant (P<0.05). After treatment,the levels of serum CA19-9,HE4 and TGF-β1 in the observation group were lower than those in control group (P<0.05). There was no difference in toxicities of Ⅲ to Ⅳ between the two groups (P>0.05). There was no difference in 3-year survival rate between the two groups (P>0.05). 【Conclusion】 NACT treatment for advanced EC can reduce the non-operable lesions to operable ones,and can inhibit levels of CA19-9,HE4,and TGF-β1 with no significant increase in toxicity.

Key words： Endometrial Neoplasms Chemotherapy,Adjuvant CA19-9 Antigen/BL Epididymal Secretory Proteins/BL Transforming Growth Factor beta1/BL

收稿日期: 2021-12-17

中图分类号:

R737.33

基金资助:陕西省榆林市科技计划项目(编号:YF-2021-63)

通讯作者: ** E-mail:317517499@qq.com

引用本文:

王榆平, 康红梅. 新辅助化疗治疗晚期子宫内膜癌患者的疗效及对患者血清CA19-9、HE4、TGF-β1水平的影响[J]. 医学临床研究, 2023, 40(3): 337-339.
WANG Yu-ping, KANG Hong-mei. Neoadjuvant Chemotherapy for Advanced Endometrial Cancer and its Effects on Serum CA19-9,HE4 and TGF-β1. JOURNAL OF CLINICAL RESEARCH, 2023, 40(3): 337-339.

链接本文:

http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2023.03.005 或 http://journal07.magtech.org.cn/yxlcyj/CN/Y2023/V40/I3/337

[1] 刘向玲,张蓉蓉. 术后化疗-放疗-化疗治疗子宫内膜癌的疗效及对患者肿瘤标志物的影响[J].医学临床研究,2022,39(7):1104-1106.
[2] RAJKUMAR S,NATH R,LANE G,et al.Advanced stage(ⅢC/Ⅳ)endometrial cancer:Role of cytoreduction and determinants of survival[J].Eur J Obstet Gynecol Reprod Biol,2019,234:26-31.
[3] KHOURI O R,FREY M K,MUSA F,et al. Neoadjuvant chemotherapy in patients with advanced endometrial cancer[J].Cancer Chemother Pharmacol,2019,84(2):281-285.
[4] NITHIN K U.CA125 is a better marker to differentiate endometrial cancer and abnormal uterine bleeding[J].Afr Health Sci,2018,18(4):972-978.
[5] 孙燕,周际昌. 临床肿瘤内科手册[M]. 北京:人民卫生出版社,2003:97-107.
[6] DE LANGE N M,EZENDAM N P M,KWON J S,et al. Neoadjuvant chemotherapy followed by surgery for advanced-stage endometrial cancer[J].Curr Oncol,2019,26(2):e226-e232.
[7] LU K H,BROADDUS R R. Endometrial cancer[J].N Engl J Med,2020,383(21):2053-2064.
[8] RABINOVICH A. Neo-adjuvant chemotherapy for advanced stage endometrial carcinoma:a glimmer of hope in select patients[J].Arch Gynecol Obstet,2016,293(1):47-53.
[9] ELIES A,RIVIÈRE S,POUGET N,et al. The role of neoadjuvant chemotherapy in ovarian cancer[J].Expert Rev Anticancer Ther,2018,18(6):555-566.
[10] NOMURA H,AOKI D,MICHIMAE H,et al. Effect of taxane plus platinum regimens vs doxorubicin plus cisplatin as adjuvant chemotherapy for endometrial cancer at a high risk of progression:a randomized clinical trial[J].JAMA Oncol,2019,5(6):833-840.
[11] NI T,LIU Y,HUANG Y,et al. Hysteroscopy combined dilatation and curettage,serum CA125 and CA19-9 play an important role in preserving fertility or endocrine function for early-stage endometrial cancer patients[J].Eur J Gynaecol Oncol,2017,38(1):49-53.
[12] BIAN J. Clinical significance of serum HE4,CA125,CA724,and CA19-9 in patients with endometrial cancer[J].Technol Cancer Res Treat,2017,16(4):435-439.
[13] 董飞天,李瑞宁. 甲磺酸阿帕替尼治疗晚期卵巢癌的疗效及对血清HE4、hK10、CA125水平的影响[J].医学临床研究,2022,39(7):1054-1057.
[14] HUANG X,WANG X,SHANG J,et al. Estrogen related receptor alpha triggers the migration and invasion of endometrial cancer cells via up regulation of TGFB1[J].Cell Adh Migr,2018,12(6):538-547.